Poinsettias: AR882 capsules approved for gout indication

Recently, Poinsettia (300723.SZ) obtained the "Drug Clinical Trial Approval Notice" approved by the State Medical Products Administration, Class 1 innovative drug AR882 capsules for gout clinical trial application was approved.

AR882 is Arthrosi, a category 1 innovative drug developed by Arthrosi. As a highly selective urate transporter-1 (URAT1) inhibitor, AR882 promotes uric acid excretion by inhibiting the reabsorption of uric acid by renal tubules and ultimately reducing serum uric acid (sUA) levels. Data from previous studies have shown that AR882 binds to uric acid transporters for a longer duration of inhibition, up to 24 hours, compared to Recinade and benbromarone. At the same time, all-day blocking of uric acid reabsorption did not result in increased renal load, indicating high renal safety.

At present, AR882 has been successfully enrolled and administered in the global clinical Phase Ⅱb trial in the United States, New Zealand, Australia and Taiwan, showing excellent efficacy and safety. In addition, AR882 has also completed preclinical studies on renal injury overseas. Clinical observations and study data show that AR882 has demonstrated good efficacy and tolerability in patients with varying degrees of renal impairment, including type 2 diabetes.